StockData
Vaccinex, Inc. logo

Vaccinex, Inc. (VCNX) stock

VCNXOTCPharmaceutical PreparationsFiscal year ends December 31
Financials through Q4 FY2024, quarter ended Dec 31, 2024Last filing: 10-K on Apr 15, 2025
$1.00−0.01 (-0.99%)

Close on Oct 19, 2026Market cap $3.22MP/E –Yield –

Vaccinex net income

Net income is the profit left for shareholders after every expense, interest and tax.

Vaccinex's net income for the twelve months ending Dec 31, 2024 was -$18.63M. For fiscal 2024 it was -$18.63M. The highest annual figure on record is -$18.63M in fiscal 2024.

Annual net income

PeriodPeriod endValueChange
FY2024Dec 31, 2024-$18.63M–
FY2023Dec 31, 2023-$20.25M–
FY2022Dec 31, 2022-$19.82M–
FY2021Dec 31, 2021-$22.38M–
FY2020Dec 31, 2020-$28.85M–
FY2019Dec 31, 2019-$31.86M–
FY2018Dec 31, 2018-$29.52M–
FY2017Dec 31, 2017-$18.72M–

Quarterly net income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2024Dec 31, 2024-$3.37M–
Q3 FY2024Sep 30, 2024-$5.73M–
Q2 FY2024Jun 30, 2024-$5.63M–
Q1 FY2024Mar 31, 2024-$3.90M–
Q4 FY2023Dec 31, 2023-$3.32M–
Q3 FY2023Sep 30, 2023-$4.91M–
Q2 FY2023Jun 30, 2023-$7.06M–
Q1 FY2023Mar 31, 2023-$4.96M–
Q4 FY2022Dec 31, 2022-$5.08M–
Q3 FY2022Sep 30, 2022-$4.76M–
Q2 FY2022Jun 30, 2022-$5.38M–
Q1 FY2022Mar 31, 2022-$4.60M–
Q4 FY2021Dec 31, 2021-$4.63M–
Q3 FY2021Sep 30, 2021-$5.21M–
Q2 FY2021Jun 30, 2021-$5.97M–
Q1 FY2021Mar 31, 2021-$6.57M–
Q4 FY2020Dec 31, 2020-$6.45M–
Q3 FY2020Sep 30, 2020-$8.75M–
Q2 FY2020Jun 30, 2020-$6.50M–
Q1 FY2020Mar 31, 2020-$7.15M–
Q4 FY2019Dec 31, 2019-$6.33M–
Q3 FY2019Sep 30, 2019-$7.64M–
Q2 FY2019Jun 30, 2019-$8.83M–
Q1 FY2019Mar 31, 2019-$9.07M–
Q4 FY2018Dec 31, 2018-$8.45M–
Q3 FY2018Sep 30, 2018-$6.60M–
Q2 FY2018Jun 30, 2018-$6.61M–
Q4 FY2017Dec 31, 2017-$2.59M–
Q3 FY2017Sep 30, 2017-$5.54M–
Q2 FY2017Jun 30, 2017-$4.88M–

More Vaccinex figures

See a number that looks wrong?